Evidence map›Paper›PMID 32907802›Full record

ArticleAnnals of the rheumatic diseases2022

Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti

Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto and 6 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Piero Ruscitti *Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Federico Bruno *Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Onorina BerardicurtiDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.ORCID http://orcid.org/0000-0002-2808-1581
Chiara AcanforaDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Viktoriya PavlychDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Pierpaolo PalumboDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Alessandro ConfortiDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Francesco CarubbiDepartment of Medicine, ASL 1 Avezzano Sulmona L'Aquila, L'Aquila, Abruzzo, Italy.ORCID http://orcid.org/0000-0003-1958-5136
Ilenia Di ColaDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Paola Di BenedettoDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.ORCID http://orcid.org/0000-0003-2927-8703
Paola CiprianiDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Davide GrassiDepartment of Clinical Medicine Life Health and Environmental Sciences, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Carlo MasciocchiDepartment of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Annamaria IagnoccoDipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Torino, Italy.
Antonio Barile *Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy.
Roberto Giacomelli *Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy roberto.giacomelli@cc.univaq.it.ORCID http://orcid.org/0000-0003-0670-9638
University of L'Aquila · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Macrophage Activation SyndromeStill's Disease, Adult-OnsetArtificial IntelligenceCross-Sectional StudiesHumansLungadult-onsetcytokinesinflammationStill's disease

Identifiers

PMID32907802
OpenAlexW3084153347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.